Chang and Lu: Prostate-specific conditional oncolytic adenovirus replication-competent human adenovirus following intraprostatic administration in the mouse. Mol Ther 1, 263274. Rodriguez R, Schuur ER, Lim HY, Henderson GA, Simons JW, and Henderson DR (1997) Prostate attenuated replication competent adenovirus (ARCA) CN706, a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res 57, 2559-2563. Russell WC (2000) Update on adenovirus and its vectors. J Gen Virol 81, 2573-2604. Shi CX, Hitt M, Ng P,and Graham FL (2002) Superior tissuespecific expression from tyrosinase and prostate-specific antigen promoters/enhancers in helper-dependent compared with first-generation adenoviral vectors. Hum Gene Ther 13, 211-224. Steiner MS, Zhang X, Wang Y, and Lu Y (2000b) Growth inhibition of prostate cancer by adenovirus expressing a novel tumor suppressor gene pHyde. Cancer Res 60, 44194425. Steiner MS, Zhang Y, and Lu Y (2000a) A fast way to generate recombinant adenovirus, a high-frequency-recombination system. J Industr Microbiol Biotechnol 24, 198-202. Steiner MS, Zhang Y, Carraher J, and Lu Y (1999) In vivo expression of prostate specific adenoviral vectors in a canine model. Cancer Gene Ther 6, 456-464. Steiner MS, Zhang Y, Farooq F, Lerner J, Wang Y, and Lu Y (2000c) Adenoviral vector containing wild type p16 suppresses prostate cancer growth and prolongs survival by inducing cell senescence. Cancer Gene Ther 7, 360-372. Yu DC, Chen Y, Seng M, Dilley J, and Henderson DR (1999b) The addition of adenovirus type 5 region E3 enables calydon
virus 787 to eliminate distant prostate tumor xenografts. Cancer Res 59, 4200-4203. Yu DC, Sakamoto GT, and Henderson DR ( 1999a) Identification of the transcriptional regulatory sequences of human kallikrein 2 and their use in the construction of calydon virus 764, an attenuated replication competent adenovirus for prostate cancer therapy. Cancer Res 59, 1498-1504.
Dr. Yi Lu
422